HLB Life Science Co., Ltd.
067630.KQFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
77
Cost of Revenue
78
Gross Profit
-2
Gross Margin
-2.1%
Operating Income
-16
Operating Margin
-20.6%
Net Income
5
Net Margin
6.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
20
EBITDA Margin
26.3%
2023
12/31/2023
Revenue
73
Cost of Revenue
74
Gross Profit
-1
Gross Margin
-0.8%
Operating Income
-18
Operating Margin
-25.0%
Net Income
-4
Net Margin
-6.1%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
17
EBITDA Margin
23.3%
2022
12/31/2022
Revenue
75
Cost of Revenue
78
Gross Profit
-3
Gross Margin
-4.6%
Operating Income
-15
Operating Margin
-20.0%
Net Income
-41
Net Margin
-54.5%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-34
EBITDA Margin
-46.2%
2021
12/31/2021
Revenue
40
Cost of Revenue
45
Gross Profit
-5
Gross Margin
-11.8%
Operating Income
-14
Operating Margin
-34.3%
Net Income
-37
Net Margin
-91.9%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-38
EBITDA Margin
-94.0%
2020
12/31/2020
Revenue
69
Cost of Revenue
68
Gross Profit
1
Gross Margin
1.5%
Operating Income
-6
Operating Margin
-8.7%
Net Income
-42
Net Margin
-60.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-40
EBITDA Margin
-57.5%